Psychedelic Business Forum 2026 brings investors, founders, and drug development leaders together around capital, regulation, and commercialization strategy

Psychedelic Business Forum 2026 centers on the business infrastructure behind psychedelic medicine, with a focus on investment, company building, regulation, and commercialization. The event positions founders, executives, investors, and service providers around the practical realities of turning psychedelic drug development into viable healthcare businesses. Programming appears geared toward market strategy rather than consumer culture, highlighting financing, partnerships, policy shifts, and the operational demands facing companies in the sector. That framing makes the forum notable as a meeting point between biotech, mental health care, and capital markets. The broader significance lies in how psychedelic medicine is moving from early excitement into a phase shaped by revenue models, reimbursement questions, trial outcomes, and regulatory timing. Business forums like this help define which companies, clinical models, and investment theses gain momentum as the field matures.